
Orexo has announced that its New Drug Application (NDA) for OX124 has been accepted for review by the US Food …
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader

